Scholars@Duke
Matthew Kyle Labriola

Matthew Kyle Labriola

Assistant Professor of Medicine
Medicine, Medical Oncology
matthew.labriola@duke.edu
20 Duke Medicine Circle, Box 103861, Durham, NC 27710
20 Duke Medicine Circle, Box 103861, Durham, NC 27710
Manage Profile
Embed Profile Data

Selected Publications

Patient engagement in designing and publishing research in prostate cancer: a scoping review.

Journal Article Future Oncol · April 4, 2024 Patients with cancer have the unique ability of being able to offer valuable insights into how cancer therapeutics may impact the overall patient experience and improve clinical outcomes. Patient engagement could therefore contribute to tailoring treatment ... Full text Link to item Cite

Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable Alterations.

Journal Article JCO Precis Oncol · April 2024 PURPOSE: There are limited data available on the real-world patterns of molecular testing in men with advanced prostate cancer. We thus sought to evaluate next-generation sequencing (NGS) testing in the United States, focused on single versus serial NGS te ... Full text Link to item Cite

Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration.

Journal Article Prostate Cancer Prostatic Dis · February 22, 2024 BACKGROUND: AR gene alterations can develop in response to pressure of testosterone suppression and androgen receptor targeting agents (ARTA). Despite this, the relevance of these gene alterations in the context of ARTA treatment and clinical outcomes rema ... Full text Link to item Cite

Considerations for Designing and Implementing a Multi-institution Undergraduate Medical Education Experience.

Journal Article J Cancer Educ · October 2023 Cancer Care Experience (CCE) is a unique elective educational program to further explore the subspecialty of oncology beyond the scope of the traditional undergraduate medical education curriculum. During the COVID-19 pandemic, CCE moved from an in-person ... Full text Link to item Cite

Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer.

Journal Article JAMA Netw Open · September 5, 2023 IMPORTANCE: Black men have higher incidence and mortality from prostate cancer. Whether precision oncology disparities affect Black men with metastatic castration-resistant prostate cancer (mCRPC) is unknown. OBJECTIVE: To compare precision medicine data a ... Full text Link to item Cite

Clinical implications of AR alterations in advanced prostate cancer: A multi-institutional collaboration.

Journal Article Res Sq · August 10, 2023 BACKGROUND: AR gene alterations can develop in response to pressure of testosterone suppression and androgen receptor targeting agents (ARTA). Despite this, the relevance of these gene alterations in the context of ARTA treatment and clinical outcomes rema ... Full text Link to item Cite

Foreign accent syndrome as a heralding manifestation of transformation to small cell neuroendocrine prostate cancer.

Journal Article BMJ Case Rep · January 30, 2023 A man in his 50s with metastatic hormone-sensitive prostate cancer, receiving androgen deprivation therapy and abiraterone acetate/prednisone, presented with an uncontrollable 'Irish brogue' accent despite no Irish background, consistent with foreign accen ... Full text Link to item Cite

Response to bipolar androgen therapy and PD-1 inhibition in a patient with metastatic castration-resistant prostate cancer and a germline CHEK2 mutation.

Journal Article BMJ Case Rep · January 18, 2023 We present the case of a patient with germline CHEK2-mutated metastatic castration-resistant prostate cancer (mCRPC) who responded to bipolar androgen therapy (BAT) combined with pembrolizumab after progressing through multiple lines of therapy. The patien ... Full text Link to item Cite

Remission of progressive metastatic castration-resistant prostate cancer during abiraterone therapy following unilateral adrenalectomy for a functioning adrenal adenoma.

Journal Article BMJ Case Rep · October 5, 2022 Despite advances and introduction of new therapies in the last decade, metastatic castration-resistant prostate cancer (mCRPC) has a poor prognosis. The development of androgen axis-targeted therapies such as abiraterone acetate, enzalutamide and darolutam ... Full text Link to item Cite

Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.

Journal Article J Immunother Cancer · October 2022 BACKGROUND: Immunotherapy combinations including ipilimumab and nivolumab are now the standard of care for untreated metastatic renal cell carcinoma (mRCC). Biomarkers of response are lacking to predict patients who will have a favorable or unfavorable res ... Full text Open Access Link to item Cite

PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer.

Journal Article Prostate Cancer Prostatic Dis · September 2022 PURPOSE: Prostate cancer is a heterogeneous disease with variable clinical outcomes. Despite numerous recent approvals of novel therapies, castration-resistant prostate cancer remains lethal. A "real-world" clinical-genomic database is urgently needed to e ... Full text Link to item Cite

How we manage grief.

Journal Article Clin Adv Hematol Oncol · September 2022 Link to item Cite

Making National Cancer Institute-Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study.

Journal Article JMIR Cancer · May 19, 2022 BACKGROUND: Expert knowledge is often shared among multidisciplinary academic teams at tumor boards (TBs) across the country, but these conversations exist in silos and do not reach the wider oncology community. OBJECTIVE: Using an oncologist-only question ... Full text Link to item Cite

Implications of androgen receptor (AR) alterations identified by genomic testing of tissue and blood from advanced prostate cancer (aPC) patients (pts).

Conference Journal of Clinical Oncology · February 20, 2022 138 Background: AR alterations such as ligand binding domain mutations and amplification evolve under the selective pressure of testosterone suppression and AR targeted agents (ARTA) such as abiraterone or enzalutamide, but their ... Full text Cite

DNA damaging therapies in patients (pts) with prostate cancer (PC) and pathogenic alterations in homologous recombination repair (HRR) genes.

Conference Journal of Clinical Oncology · February 20, 2022 129 Background: Pathogenic HRR gene mutations may confer sensitivity to PARP inhibitors (PARPi) and/or platinum chemotherapy (chemo). While pts harboring mutations in BRCA1/2 appear to benefit from these DNA damaging therapeutics ... Full text Cite

Management of men with metastatic castration-resistant prostate cancer following potent androgen receptor inhibition: a review of novel investigational therapies.

Journal Article Prostate Cancer Prostatic Dis · June 2021 BACKGROUND: Androgen-targeted therapy and chemotherapy are currently the mainstay of treatment in metastatic castration resistant prostate cancer (mCRPC). When progression occurs despite these therapeutic strategies, additional FDA-approved treatment optio ... Full text Link to item Cite

Patient engagement in designing and publishing research in prostate cancer: a scoping review.

Journal Article Future Oncol · April 4, 2024 Patients with cancer have the unique ability of being able to offer valuable insights into how cancer therapeutics may impact the overall patient experience and improve clinical outcomes. Patient engagement could therefore contribute to tailoring treatment ... Full text Link to item Cite

Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable Alterations.

Journal Article JCO Precis Oncol · April 2024 PURPOSE: There are limited data available on the real-world patterns of molecular testing in men with advanced prostate cancer. We thus sought to evaluate next-generation sequencing (NGS) testing in the United States, focused on single versus serial NGS te ... Full text Link to item Cite

Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration.

Journal Article Prostate Cancer Prostatic Dis · February 22, 2024 BACKGROUND: AR gene alterations can develop in response to pressure of testosterone suppression and androgen receptor targeting agents (ARTA). Despite this, the relevance of these gene alterations in the context of ARTA treatment and clinical outcomes rema ... Full text Link to item Cite

Considerations for Designing and Implementing a Multi-institution Undergraduate Medical Education Experience.

Journal Article J Cancer Educ · October 2023 Cancer Care Experience (CCE) is a unique elective educational program to further explore the subspecialty of oncology beyond the scope of the traditional undergraduate medical education curriculum. During the COVID-19 pandemic, CCE moved from an in-person ... Full text Link to item Cite

Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer.

Journal Article JAMA Netw Open · September 5, 2023 IMPORTANCE: Black men have higher incidence and mortality from prostate cancer. Whether precision oncology disparities affect Black men with metastatic castration-resistant prostate cancer (mCRPC) is unknown. OBJECTIVE: To compare precision medicine data a ... Full text Link to item Cite

Clinical implications of AR alterations in advanced prostate cancer: A multi-institutional collaboration.

Journal Article Res Sq · August 10, 2023 BACKGROUND: AR gene alterations can develop in response to pressure of testosterone suppression and androgen receptor targeting agents (ARTA). Despite this, the relevance of these gene alterations in the context of ARTA treatment and clinical outcomes rema ... Full text Link to item Cite

Foreign accent syndrome as a heralding manifestation of transformation to small cell neuroendocrine prostate cancer.

Journal Article BMJ Case Rep · January 30, 2023 A man in his 50s with metastatic hormone-sensitive prostate cancer, receiving androgen deprivation therapy and abiraterone acetate/prednisone, presented with an uncontrollable 'Irish brogue' accent despite no Irish background, consistent with foreign accen ... Full text Link to item Cite

Response to bipolar androgen therapy and PD-1 inhibition in a patient with metastatic castration-resistant prostate cancer and a germline CHEK2 mutation.

Journal Article BMJ Case Rep · January 18, 2023 We present the case of a patient with germline CHEK2-mutated metastatic castration-resistant prostate cancer (mCRPC) who responded to bipolar androgen therapy (BAT) combined with pembrolizumab after progressing through multiple lines of therapy. The patien ... Full text Link to item Cite

Remission of progressive metastatic castration-resistant prostate cancer during abiraterone therapy following unilateral adrenalectomy for a functioning adrenal adenoma.

Journal Article BMJ Case Rep · October 5, 2022 Despite advances and introduction of new therapies in the last decade, metastatic castration-resistant prostate cancer (mCRPC) has a poor prognosis. The development of androgen axis-targeted therapies such as abiraterone acetate, enzalutamide and darolutam ... Full text Link to item Cite

Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.

Journal Article J Immunother Cancer · October 2022 BACKGROUND: Immunotherapy combinations including ipilimumab and nivolumab are now the standard of care for untreated metastatic renal cell carcinoma (mRCC). Biomarkers of response are lacking to predict patients who will have a favorable or unfavorable res ... Full text Open Access Link to item Cite

PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer.

Journal Article Prostate Cancer Prostatic Dis · September 2022 PURPOSE: Prostate cancer is a heterogeneous disease with variable clinical outcomes. Despite numerous recent approvals of novel therapies, castration-resistant prostate cancer remains lethal. A "real-world" clinical-genomic database is urgently needed to e ... Full text Link to item Cite

How we manage grief.

Journal Article Clin Adv Hematol Oncol · September 2022 Link to item Cite

Making National Cancer Institute-Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study.

Journal Article JMIR Cancer · May 19, 2022 BACKGROUND: Expert knowledge is often shared among multidisciplinary academic teams at tumor boards (TBs) across the country, but these conversations exist in silos and do not reach the wider oncology community. OBJECTIVE: Using an oncologist-only question ... Full text Link to item Cite

Implications of androgen receptor (AR) alterations identified by genomic testing of tissue and blood from advanced prostate cancer (aPC) patients (pts).

Conference Journal of Clinical Oncology · February 20, 2022 138 Background: AR alterations such as ligand binding domain mutations and amplification evolve under the selective pressure of testosterone suppression and AR targeted agents (ARTA) such as abiraterone or enzalutamide, but their ... Full text Cite

DNA damaging therapies in patients (pts) with prostate cancer (PC) and pathogenic alterations in homologous recombination repair (HRR) genes.

Conference Journal of Clinical Oncology · February 20, 2022 129 Background: Pathogenic HRR gene mutations may confer sensitivity to PARP inhibitors (PARPi) and/or platinum chemotherapy (chemo). While pts harboring mutations in BRCA1/2 appear to benefit from these DNA damaging therapeutics ... Full text Cite

Management of men with metastatic castration-resistant prostate cancer following potent androgen receptor inhibition: a review of novel investigational therapies.

Journal Article Prostate Cancer Prostatic Dis · June 2021 BACKGROUND: Androgen-targeted therapy and chemotherapy are currently the mainstay of treatment in metastatic castration resistant prostate cancer (mCRPC). When progression occurs despite these therapeutic strategies, additional FDA-approved treatment optio ... Full text Link to item Cite

LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types.

Journal Article J Immunother Cancer · March 2021 BACKGROUND: Low-density lipoprotein receptor-related protein 1b (encoded by LRP1B) is a putative tumor suppressor, and preliminary evidence suggests LRP1B-mutated cancers may have improved outcomes with immune checkpoint inhibitors (ICI). METHODS: We condu ... Full text Open Access Link to item Cite

Differences in Toxicity and Outcomes in Clinical Trial Participants From Minority Populations.

Journal Article American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · March 2021 Black men have a higher prevalence of and mortality rate from prostate cancer compared with White men and have been shown to present with more aggressive and later-stage disease. How prostate cancer treatment affects these racial disparities is still uncle ... Full text Cite

PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma.

Journal Article Clin Genitourin Cancer · December 2020 BACKGROUND: Immune checkpoint inhibitors are now standard of care for many patients with metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC). Given real-world limitations in programmed death-ligand 1 (PD-L1) testing, concordanc ... Full text Link to item Cite

Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients.

Journal Article Oncoimmunology · June 10, 2020 BACKGROUND: Biomarkers predicting immunotherapy response in metastatic renal cell cancer (mRCC) are lacking. PD-L1 immunohistochemistry is a complementary diagnostic for immune checkpoint inhibitors (ICIs) in mRCC, but has shown minimal clinical utility an ... Full text Link to item Cite

Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.

Journal Article J Immunother Cancer · March 2020 BACKGROUND: Immune checkpoint inhibitors (ICIs) have expanded treatment options for metastatic renal cell carcinoma (mRCC); however, there are limited predictive biomarkers for response to ICIs in this indication, with programmed death-ligand 1 (PD-L1) sta ... Full text Link to item Cite

Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma.

Journal Article Clin Genitourin Cancer · June 2019 The incidence of renal-cell carcinoma has been increasing each year, with nearly one third of new cases diagnosed at advanced or metastatic stage. The advent of targeted therapies for metastatic renal-cell carcinoma (mRCC) has underscored the need to subty ... Full text Link to item Cite

Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC).

Conference Journal of Clinical Oncology · May 20, 2019 e16079 Background: ICIs have revolutionized treatment for mRCC; however there are limited predictive biomarkers for response to ICIs. PD-L1 status is still controversial, demonstrating little predictive utility in mRCC. TMB is pr ... Full text Cite

Immune checkpoint inhibitor response in tumors with LRP1B variants.

Conference Journal of Clinical Oncology · May 20, 2019 e14291 Background: Low-density lipoprotein receptor-related protein 1B (LRP1B) is a putative tumor suppressor gene spanning > 500 kb on chromosome 2. A melanoma study previously reported enrichment of LRP1B mutations in respon ... Full text Cite

Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC).

Conference Journal of Clinical Oncology · May 20, 2019 2595 Background: ICIs are now standard of care for mRCC; however, there are few biomarkers to predict ICI response. Recent data from atezolizumab/bevacizumab trials in mRCC suggest tumors with high Teff Full text Cite

Concordance between PD-L1 assays for metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC).

Conference Journal of Clinical Oncology · May 20, 2019 e14259 Background: Immune checkpoint inhibitors (ICIs) are standard of care for mRCC and mUC patients (pts). PD-L1 status is gaining importance as a predictive biomarker, particularly for cisplatin-ineligible mUC. PD-L1 positivit ... Full text Cite

Cell proliferation as a biomarker for response to immune checkpoint inhibitors in highly inflamed renal cell carcinoma.

Conference Journal of Clinical Oncology · March 10, 2019 61 Background: Cell proliferation is an important marker of survival in many tumors and we hypothesized that this attribute could be related to response to immune checkpoint inhibitors in RCC. Previously we reported (SITC 2018) m ... Full text Cite

Cell proliferation as a biomarker for response to immune checkpoint inhibitors in PD-L1 negative renal cell carcinoma.

Conference Journal of Clinical Oncology · March 10, 2019 62 Background: Cell proliferation is an important marker of survival in many tumors, and we hypothesized that this attribute could be related to response to immune checkpoint inhibitors (ICIs) in RCC. Previously we reported (SITC ... Full text Cite

Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC).

Conference Journal of Clinical Oncology · March 10, 2019 63 Background: ICIs are now standard of care for mRCC; however, there are few biomarkers to predict ICI response. Recent data from atezolizumab/bevacizumab trials in mRCC suggest tumors with high Teff Full text Cite

Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC).

Conference Journal of Clinical Oncology · March 1, 2019 589 Background: ICIs have revolutionized treatment for mRCC; however there are limited predictive biomarkers for response to ICIs. PD-L1 status is still controversial demonstrating little predictive utility in mRCC. TMB is predic ... Full text Cite

Characterization of genomic alterations as biomarkers of immune checkpoint inhibitor (ICI) response in metastatic urothelial carcinoma (mUC).

Conference Journal of Clinical Oncology · March 1, 2019 400 Background: ICIs have expanded therapeutic options for mUC patients (pts); however, biomarkers such as PD-L1 have not served as reliable predictors of treatment efficacy. High tumor mutation burden (TMB) has been previously d ... Full text Cite

Concordance between PD-L1 assays for metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC).

Conference Journal of Clinical Oncology · March 1, 2019 577 Background: Immune checkpoint inhibitors (ICIs) are now standard of care for mRCC and mUC patients (pts). PD-L1 status is gaining importance as a predictive biomarker, particularly for cisplatin-ineligible mUC. Four different ... Full text Cite

Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC).

Conference Journal of Clinical Oncology · March 1, 2019 607 Background: ICIs are now standard of care for mRCC; however, there are few biomarkers to predict ICI response. Recent data from atezolizumab/bevacizumab trials in mRCC suggest tumors with high Teff Full text Cite

Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients.

Journal Article J Immunother Cancer · February 1, 2019 BACKGROUND: Resistance to immune checkpoint inhibitors (ICIs) has been linked to local immunosuppression independent of major ICI targets (e.g., PD-1). Clinical experience with response prediction based on PD-L1 expression suggests that other factors influ ... Full text Link to item Cite

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors.

Journal Article J Immunother Cancer · January 24, 2019 BACKGROUND: PD-L1 immunohistochemistry (IHC) has been traditionally used for predicting clinical responses to immune checkpoint inhibitors (ICIs). However, there are at least 4 different assays and antibodies used for PD-L1 IHC, each developed with a diffe ... Full text Link to item Cite

Consent for organ donation after circulatory death at U.S. transplant centers.

Journal Article AJOB Empir Bioeth · 2017 BACKGROUND: Despite calls for a controlled organ donation after circulatory death (cDCD) consent process that is more rigorous, consistent, and transparent, little is known about the cDCD consent processes utilized by U.S. hospitals. The objective of this ... Full text Link to item Cite

Fabrication of bionanocomposites comprising flat nanocrystals of calcium in collagen fibers exhibiting hardness comparable to metal

Journal Article RSC Advances · November 21, 2013 In nature's biomineralization process, living organisms naturally incorporate insoluble mineral compounds into their nano and molecular scale biological structures which results in formation of unusually hard but significantly less brittle biominerals. Mim ... Full text Cite

Engineered bone-inspired multicomponent bionanocomposite scaffolds with tunable hardness and modulus

Conference Materials Research Society Symposium Proceedings · December 1, 2012 We show a novel, bioengineered, moldable platform for bone regeneration composed of porous bionanocomposite scaffolds made of components that are normally found in bone tissue (calcium, collagen, carbonate, sodium, and phosphorous). To accommodate high- or ... Full text Cite